Omeros (OMER)
(Real Time Quote from BATS)
$3.79 USD
+0.15 (4.12%)
Updated Sep 9, 2024 12:52 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Omeros Corporation [OMER]
Reports for Purchase
Showing records 361 - 380 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Pivotal Eye Surgery Data is Expected - Upgrading to Market Outperform
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Omeros Corporation
Industry: Medical - Products
Pivotal Eye Surgery Data is Expected - Upgrading to Market Outperform
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Omeros Corporation
Industry: Medical - Products
OMS302 Update: We See Transforming Clinical Data in Q1 2012. Reiterate OUTPERFORM. FV Goes to $15.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q3 Results: We Believe Pipeline Progress May Partnerships and Transforming Clinical Data Reiterate OUTPERFORM. FV Goes to $13.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
OMS302 Begins Phase 3 To Reduce Post-Operative Pain and Maintain Mydriasis During Intra-Ocular Lens Replacement
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Four Additional Orphan GPCRs Have Been Unlocked. We Believe a Growing Collection of Unlocked GPCRs Is Likely To Lead to Lucrative Pharma Partnerships
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.